EP3420077A4 - Traitement au moyen d'une nucléase virale et oncovirale - Google Patents

Traitement au moyen d'une nucléase virale et oncovirale Download PDF

Info

Publication number
EP3420077A4
EP3420077A4 EP17757316.9A EP17757316A EP3420077A4 EP 3420077 A4 EP3420077 A4 EP 3420077A4 EP 17757316 A EP17757316 A EP 17757316A EP 3420077 A4 EP3420077 A4 EP 3420077A4
Authority
EP
European Patent Office
Prior art keywords
oncoviral
viral
nuclease treatment
nuclease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17757316.9A
Other languages
German (de)
English (en)
Other versions
EP3420077A1 (fr
Inventor
Stephen R. Quake
Derek D. Sloan
Xin Cindy XIONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agenovir Corp
Original Assignee
Agenovir Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenovir Corp filed Critical Agenovir Corp
Publication of EP3420077A1 publication Critical patent/EP3420077A1/fr
Publication of EP3420077A4 publication Critical patent/EP3420077A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
EP17757316.9A 2016-02-25 2017-02-24 Traitement au moyen d'une nucléase virale et oncovirale Withdrawn EP3420077A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662299839P 2016-02-25 2016-02-25
US201662299792P 2016-02-25 2016-02-25
PCT/US2017/019390 WO2017147446A1 (fr) 2016-02-25 2017-02-24 Traitement au moyen d'une nucléase virale et oncovirale

Publications (2)

Publication Number Publication Date
EP3420077A1 EP3420077A1 (fr) 2019-01-02
EP3420077A4 true EP3420077A4 (fr) 2019-12-25

Family

ID=59686633

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17757316.9A Withdrawn EP3420077A4 (fr) 2016-02-25 2017-02-24 Traitement au moyen d'une nucléase virale et oncovirale

Country Status (4)

Country Link
EP (1) EP3420077A4 (fr)
AU (1) AU2017223964A1 (fr)
CA (1) CA3015353A1 (fr)
WO (1) WO2017147446A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6261500B2 (ja) 2011-07-22 2018-01-17 プレジデント アンド フェローズ オブ ハーバード カレッジ ヌクレアーゼ切断特異性の評価および改善
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
WO2016022363A2 (fr) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Protéines cas9 comprenant des intéines dépendant de ligands
CN108289932A (zh) 2015-05-22 2018-07-17 D·D·格恩金 胞外dna作为神经变性的治疗靶点
EP3355954A4 (fr) * 2015-09-29 2020-01-08 Agenovir Corporation Méthodes et compositions d'administration
US20190225955A1 (en) 2015-10-23 2019-07-25 President And Fellows Of Harvard College Evolved cas9 proteins for gene editing
KR102547316B1 (ko) 2016-08-03 2023-06-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
EP3592777A1 (fr) 2017-03-10 2020-01-15 President and Fellows of Harvard College Éditeur de base cytosine à guanine
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
WO2019023680A1 (fr) 2017-07-28 2019-01-31 President And Fellows Of Harvard College Procédés et compositions pour l'évolution d'éditeurs de bases à l'aide d'une évolution continue assistée par phage (pace)
WO2019139645A2 (fr) 2017-08-30 2019-07-18 President And Fellows Of Harvard College Éditeurs de bases à haut rendement comprenant une gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
WO2019135816A2 (fr) * 2017-10-23 2019-07-11 The Broad Institute, Inc. Nouveaux modificateurs d'acide nucléique
AU2019209770A1 (en) 2018-01-16 2020-09-03 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
CN113395975A (zh) * 2018-11-20 2021-09-14 宾夕法尼亚州大学信托人 用于靶向血脑屏障的组合物和方法
CA3130488A1 (fr) 2019-03-19 2020-09-24 David R. Liu Procedes et compositions pour l'edition de sequences nucleotidiques
WO2021011365A1 (fr) * 2019-07-12 2021-01-21 Dmitry Dmitrievich Genkin Traitement de maladies par expression d'une enzyme à activité désoxyribonucléase (dnase)
GB2614813A (en) 2020-05-08 2023-07-19 Harvard College Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2023215913A2 (fr) * 2022-05-06 2023-11-09 The Children's Hospital Of Philadelphia Compositions et méthodes pour le diagnostic et le traitement de la covid-19 sévère et d'autres troubles auto-immuns inflammatoires
CN115227834A (zh) * 2022-06-02 2022-10-25 中国人民解放军海军军医大学 通过基因编辑技术联合dna损伤修复抑制剂特异杀伤癌细胞的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184259A1 (fr) * 2014-05-30 2015-12-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions et méthodes pour traiter des infections virales latentes
EP2966170A1 (fr) * 2014-07-10 2016-01-13 Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - Inactivation du virus d'hépatite B

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393396B2 (en) * 2002-02-14 2016-07-19 Gholam A. Peyman Method and composition for hyperthermally treating cells
EP3131927B8 (fr) * 2014-04-14 2020-12-23 Cellectis Récepteurs antigéniques chimériques spécifiques de bcma (cd269), utiles dans l'immunothérapie du cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184259A1 (fr) * 2014-05-30 2015-12-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions et méthodes pour traiter des infections virales latentes
EP2966170A1 (fr) * 2014-07-10 2016-01-13 Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - Inactivation du virus d'hépatite B

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
R. H. WIJDEVEN ET AL: "Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer", CANCER RESEARCH, vol. 75, no. 19, 10 August 2015 (2015-08-10), US, pages 4176 - 4187, XP055642176, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-15-0380 *
See also references of WO2017147446A1 *
VARIOUS: "Abstracts, 20th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT); Washington, DC, USA; May 10 -13, 2017", MOLECULAR THERAPY, vol. 25, 1 May 2017 (2017-05-01), pages 1 - 363, XP055466872, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2017.04.025 *
YI LANG ET AL: "CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1866, no. 2, 15 September 2016 (2016-09-15), pages 197 - 207, XP029826231, ISSN: 0304-419X, DOI: 10.1016/J.BBCAN.2016.09.002 *

Also Published As

Publication number Publication date
AU2017223964A1 (en) 2018-09-06
EP3420077A1 (fr) 2019-01-02
WO2017147446A1 (fr) 2017-08-31
CA3015353A1 (fr) 2017-08-31

Similar Documents

Publication Publication Date Title
EP3420077A4 (fr) Traitement au moyen d'une nucléase virale et oncovirale
EP3331571A4 (fr) Compositions et procédés pour traiter des infections virales
EP3160405A4 (fr) Traitement de l'oreille
EP3261641A4 (fr) Traitement de la pancréatite
EP3256113A4 (fr) Traitement de l'hypoparathyroïdie
ZA201705633B (en) A new quinoline derivative for use in the treatment and prevention of viral infections
IL273932A (en) Methods of treatment and prevention of viral infection
HK1258276A1 (zh) 用於治療hiv的化合物和組合
EP3222240A4 (fr) Outil de traitement à haute fréquence et système de traitement à haute fréquence
EP3222239A4 (fr) Outil de traitement et système de traitement
EP3166615A4 (fr) Procédés pour le traitement d'infections par le virus de l'hépatite b et le virus de l'hépatite d
EP3525703A4 (fr) Dispositifs et procédés de traitement
IL263368A (en) Prevention and treatment of viral infections
HK1247963A1 (zh) 用於hiv的治療的基因療法及其用途
EP3362091A4 (fr) Polythérapie
HK1252343A1 (zh) 用於治療病毒感染的組合物和方法
HK1253557A1 (zh) 純化和/或病毒滅活的方法
EP3302207A4 (fr) Appareils et procédés de traitement de surface
EP3107473A4 (fr) Dispositifs de traitement et indications en temps réel
EP3182915A4 (fr) Systèmes et méthodes de traitement de l'os
EP3353304A4 (fr) Traitement de la conjonctivite virale à l'aide de la ranpirnase et/ou de l'amphinase
GB201404372D0 (en) Assay and treatment
HK1258093A1 (zh) 病毒新表位及其用途
EP3268034A4 (fr) Virus non neuro-invasifs et leurs utilisations
EP3119307A4 (fr) Dispositifs et procédés de traitement de la peau

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180925

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191122

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/113 20100101ALI20191118BHEP

Ipc: C12N 15/09 20060101ALI20191118BHEP

Ipc: G01N 33/574 20060101ALI20191118BHEP

Ipc: C07H 21/04 20060101ALI20191118BHEP

Ipc: A61K 9/127 20060101ALI20191118BHEP

Ipc: A61P 31/12 20060101ALI20191118BHEP

Ipc: C12N 15/12 20060101ALI20191118BHEP

Ipc: C12N 9/22 20060101AFI20191118BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200623